CSS
TSHA icon

Cubist Systematic Strategies’s Taysha Gene Therapies TSHA Stock Holding History

Cubist Systematic Strategies’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-161,100
Closed -$462K – 4035
2024
Q1 		$462K Buy
161,100
+112,666
+233% +$235K ﹤0.01% 2652
2023
Q4 		$85.7K Buy
+48,434
New +$96.6K ﹤0.01% 3206
2023
Q1 		– Sell
-40,301
Closed -$91.1K – 4436
2022
Q4 		$91.1K Buy
+40,301
New +$81.6K ﹤0.01% 3820
2022
Q2 		– Sell
-33,694
Closed -$220K – 4578
2022
Q1 		$220K Buy
33,694
+14,059
+72% +$105K ﹤0.01% 3004
2021
Q4 		$229K Buy
+19,635
New +$296K ﹤0.01% 2954
2021
Q1 		– Sell
-4,453
Closed -$118K – 2980
2020
Q4 		$118K Buy
+4,453
New +$95.9K ﹤0.01% 2378

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cubist Systematic Strategies's TSHA Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 161,100 shares — an estimated $462K sold.

Cubist Systematic Strategies first reported a position in TSHA in Q4 2020 and held it in 6 quarters. The position peaked at $462K in Q1 2024. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 161,100 Taysha Gene Therapies shares in Q2 2024, an estimated $462K.
  • Cubist Systematic Strategies first reported a position in Taysha Gene Therapies in Q4 2020 and held it in 6 quarters.
  • Cubist Systematic Strategies's Taysha Gene Therapies position peaked at $462K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.